Latest Content

Oculis launches a genotype-guided dry eye trial testing licaminlimab eye drops, targeting TNFR1 patients and measuring Day 29 ocular discomfort improvement.

The lens is scheduled to become available in the US in fall 2026.

The study, conducted through the OHDSI network, analyzed records from 227,971 new users of semaglutide.

Daniel C. Brocks, MD, BostonSight chief medical officer, discusses a few of the company's studies, the patients they serve, and what the broader eye care community may be missing.

The free web-based tool guides eye care providers through evidence-based amblyopia diagnosis and treatment without requiring pediatric subspecialty training.

LENZ Therapeutics licenses FDA-approved presbyopia drop to Everest Medicines for Greater China; NDA under review by NMPA with approval anticipated in Q1 2027.

Researchers analyzed data from 13 randomized controlled trials involving children and adolescents with myopia.

Clark Chang, OD, MSA, MSc, FAAO, FSLS, and Susan Gromacki, OD, MS, FAAO, FSLS, provide insights into their expertise.

The strength of our referral relationships defines the quality of our patients' eye health journey.

Researchers from Yale School of Medicine weigh in on what everyday clinicians can take away from their findings.

Myopia management is rarely straightforward.

The topical synthetic peptide receives orphan drug and fast track status and enters phase 2 as a first-in-class treatment for a rare degenerative corneal disease.

Yale School of Medicine researchers outline their findings and the methods of their researcher in an exclusive interview with Optometry Times.